Summit also reports that on Thursday, January 15, 2026, Drew Clark, President and Chief Executive Officer, and members of the executive management team and board opened the market to celebrate ...
The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback